Journal
EMERGING INFECTIOUS DISEASES
Volume 28, Issue 7, Pages 1355-1365Publisher
CENTERS DISEASE CONTROL & PREVENTION
DOI: 10.3201/eid2807.220033
Keywords
-
Categories
Funding
- Occitanie Region
- Agence Nationale de la Recherche
- Agence Nationale de la Recherche Maladies Infectieuses Emergentes [ANRS0151]
Ask authors/readers for more resources
The study found that the Omicron variant has a greater growth advantage compared to the Delta variant and can generate significant COVID-19 activity in hospitals in France. Additionally, the magnitude of the BA.2 wave depends on the relaxation of control measures, but remains lower than that of BA.1 in median scenarios.
We analyzed 324,734 SARS-CoV-2 variant screening tests from France enriched with 16,973 whole-genome sequences sampled during September 1, 2021-February 28, 2022. Results showed the estimated growth advantage of the Omicron variant over the Delta variant to be 105% (95% CI 96%-114%) and that of the BA.2 lineage over the BA.1 lineage to be 49% (95% CI 44%-52%). Quantitative PCR cycle threshold values were consistent with an increased ability of Omicron to generate breakthrough infections. Epidemiologic modeling shows that, in spite of its decreased virulence, the Omicron variant can generate important critical COVID-19 activity in hospitals in France. The magnitude of the BA.2 wave in hospitals depends on the level of relaxing of control measures but remains lower than that of BA.1 in median scenarios.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available